Evolent Health (EVH) Cash & Equivalents (2015 - 2026)

Evolent Health has reported Cash & Equivalents for 12 years, with the latest figure at $142.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 42.4% year-over-year to $142.0 million; the trailing twelve-month figure through Mar 2026 stood at $142.0 million (down 42.4% YoY), and the FY2025 full-year result was $151.9 million, up 45.73% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $142.0 million, down from $151.9 million in the prior quarter.
• The five-year high for Cash & Equivalents was $246.5 million in Q1 2025, with the low at $96.6 million in Q3 2024.
• Average Cash & Equivalents over 5 years is $158.9 million, with a median of $156.8 million recorded in 2022.
• Year-over-year, Cash & Equivalents tumbled 47.66% in 2024 and jumped 49.29% in 2025.
• Tracing EVH's Cash & Equivalents over 5 years: stood at $188.2 million in 2022, then grew by 2.46% to $192.8 million in 2023, then slumped by 45.96% to $104.2 million in 2024, then soared by 45.73% to $151.9 million in 2025, then dropped by 6.49% to $142.0 million in 2026.
• The last three Cash & Equivalents figures came in at $142.0 million (Q1 2026), $151.9 million (Q4 2025), and $116.6 million (Q3 2025), per Business Quant data.

Peer Comparison